

## EQA round: IGIT1/24 - Immunopathology of GIT

Deadline: 8.3.2024

Setup: groups - M (measurement principle)

AV = assigned value

N<sub>tot</sub> = total number of the resultsN<sub>eva</sub> = number of the results assessed

CVP = consensus of all participants

N<sub>rel</sub> = relative number of the resultsN<sub>suc</sub> = number of successful results

&gt;&gt;&gt; ... expected result

S<sub>rel</sub> = relative success

&gt; ... acceptable result

± ... result not assessed

Test Sample Group	Frequency of the results					Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]	
<b>Set 1</b>								
(595) anti-gliadin IgA (deamidated)		76			76	76	100	
<b>Sample A1</b>		76			76	76	100	
(1) Fluorescent methods	CVP >>>	1	1,3	Negative				
(2) EIA methods	CVP >>>	58	76	Negative				
(5) LIA, ILMA	CVP >>>	13	17	Negative				
(99) Another measurement principle	CVP >>>	4	5,3	Negative				
<b>Sample B1</b>		76			76	76	100	
(1) Fluorescent methods	CVP >>>	1	1,3	Positive				
(2) EIA methods	CVP >>>	58	76	Positive				
(5) LIA, ILMA	CVP >>>	13	17	Positive				
(99) Another measurement principle	CVP >>>	4	5,3	Positive				
(594) anti-gliadin IgG (deamidated)		80			80	80	100	
<b>Sample A1</b>		80			80	80	100	
(0) Not specified	CVP >>>	1	1,3	Negative				
(1) Fluorescent methods	CVP >>>	1	1,3	Negative				
(2) EIA methods	CVP >>>	60	75	Negative				
(5) LIA, ILMA	CVP >>>	14	18	Negative				
(99) Another measurement principle	CVP >>>	4	5	Negative				
<b>Sample B1</b>		80			80	80	100	
(0) Not specified	CVP >>>	1	1,3	Positive				
(1) Fluorescent methods	CVP >>>	1	1,3	Positive				
(2) EIA methods	CVP >>>	60	75	Positive				
(5) LIA, ILMA	CVP >>>	14	18	Positive				
(99) Another measurement principle	CVP >>>	4	5	Positive				
<b>Set 2</b>								
(424) anti-endomysium IgA		69			69	69	100	
<b>Sample A2</b>		69			69	69	100	
(1) Fluorescent methods	CVP >>>	68	99	Negative				
(2) EIA methods	CVP >>>	1	1,4	Negative				
<b>Sample B2</b>		69			69	69	100	
(1) Fluorescent methods	CVP >>>	68	99	Positive				
(2) EIA methods	CVP >>>	1	1,4	Positive				
(425) anti-transglutaminase IgA		84			84	84	100	
<b>Sample A2</b>		84			84	84	100	
(1) Fluorescent methods	CVP >>>	1	1,2	Negative				
(2) EIA methods	CVP >>>	62	74	Negative				
(5) LIA, ILMA	CVP >>>	19	23	Negative				
(99) Another measurement principle	CVP >>>	2	2,4	Negative				
<b>Sample B2</b>		84			84	84	100	
(1) Fluorescent methods	CVP >>>	1	1,2	Positive				
(2) EIA methods	CVP >>>	62	74	Positive				
(5) LIA, ILMA	CVP >>>	19	23	Positive				
(99) Another measurement principle	CVP >>>	2	2,4	Positive				
<b>Set 3</b>								
(592) anti-Saccharomyces cerevisiae IgA		63			63	63	100	
<b>Sample A3</b>		63			63	63	100	
(1) Fluorescent methods	CVP >>>	22	35	Positive				
(2) EIA methods	CVP >>>	39	62	Positive				
(5) LIA, ILMA	CVP >>>	2	3,2	Positive				
<b>Sample B3</b>		63			63	63	100	
(1) Fluorescent methods	CVP >>>	22	35	Negative				
(2) EIA methods	CVP >>>	39	62	Negative				
(5) LIA, ILMA	CVP >>>	2	3,2	Negative				
(593) anti-Saccharomyces cerevisiae IgG		57			57	57	100	
<b>Sample A3</b>		57			57	57	100	
(0) Not specified	CVP >>>	1	1,8	Positive				
(1) Fluorescent methods	CVP >>>	19	33	Positive				
(2) EIA methods	CVP >>>	35	61	Positive				
(5) LIA, ILMA	CVP >>>	2	3,5	Positive				
<b>Sample B3</b>		57			57	57	100	
(0) Not specified	CVP >>>	1	1,8	Negative				
(1) Fluorescent methods	CVP >>>	19	33	Negative				

## EQA round: IGIT1/24 - Immunopathology of GIT

Deadline: 8.3.2024

Setup: groups - M (measurement principle)

Test Sample Group	Frequency of the results				Success		
	AV	N <sub>tot</sub>	N <sub>rel</sub> [%]	Result	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub> [%]
(2) EIA methods	CVP >>>	35	61	Negative			
(5) LIA, ILMA	CVP >>>	2	3,5	Negative			